CY1106467T1 - Ελεγχομενη συνθεση ζιπρασιδονης - Google Patents

Ελεγχομενη συνθεση ζιπρασιδονης

Info

Publication number
CY1106467T1
CY1106467T1 CY20071100629T CY071100629T CY1106467T1 CY 1106467 T1 CY1106467 T1 CY 1106467T1 CY 20071100629 T CY20071100629 T CY 20071100629T CY 071100629 T CY071100629 T CY 071100629T CY 1106467 T1 CY1106467 T1 CY 1106467T1
Authority
CY
Cyprus
Prior art keywords
controlled
ziprasidone
ziprasidone composition
chloroziprasidone
composition
Prior art date
Application number
CY20071100629T
Other languages
English (en)
Inventor
Frank Robert Busch
Adam Worth Grobin
Harry Ralph Howard, Jr
Kyle Robert Leeman
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106467(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of CY1106467T1 publication Critical patent/CY1106467T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Η υποκείμενη εφεύρεση παρέχει μία σύνθεση ζιπρασιδόνης που περιλαμβάνει όχι περισσότερο από 1000 ppm δες-χλωροζιπρασιδόνης, κατά προτίμηση δε όχι περισσότερο από περίπου 500 ppm δες-χλωροζιπρασιδόνης, και περισσότερο δε κατά προτίμηση όχι περισσότερο από περίπου 100 ppm δες-χλωροζιπρασιδόνης. Επίσης παρέχονται μέθοδοι για την συνθετοποίηση και την χρήση συνθέσεων ζιπρασιδόνης αυτού του είδους.
CY20071100629T 2002-02-20 2007-05-10 Ελεγχομενη συνθεση ζιπρασιδονης CY1106467T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27
PCT/IB2003/000642 WO2003070246A1 (en) 2002-02-20 2003-02-17 Controlled synthesis of ziprasidone and compositions thereof

Publications (1)

Publication Number Publication Date
CY1106467T1 true CY1106467T1 (el) 2012-01-25

Family

ID=27761437

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100629T CY1106467T1 (el) 2002-02-20 2007-05-10 Ελεγχομενη συνθεση ζιπρασιδονης

Country Status (41)

Country Link
EP (1) EP1476162B1 (el)
JP (1) JP4554938B2 (el)
KR (1) KR100773622B1 (el)
CN (2) CN1635892A (el)
AP (1) AP2004003103A0 (el)
AR (1) AR038563A1 (el)
AT (1) ATE359787T1 (el)
AU (2) AU2003206035A1 (el)
BR (1) BR0307833A (el)
CA (1) CA2475302C (el)
CO (1) CO5611138A2 (el)
CY (1) CY1106467T1 (el)
DE (1) DE60313289T2 (el)
DK (1) DK1476162T3 (el)
EA (1) EA007866B1 (el)
EC (1) ECSP045239A (el)
ES (1) ES2283745T3 (el)
GE (1) GEP20074030B (el)
GT (1) GT200300040A (el)
HR (1) HRP20040711A2 (el)
IL (1) IL163277A (el)
IS (1) IS7344A (el)
MA (1) MA27177A1 (el)
MX (1) MXPA04006993A (el)
MY (1) MY139523A (el)
NO (2) NO20043902L (el)
NZ (1) NZ534443A (el)
OA (1) OA12774A (el)
PA (1) PA8567001A1 (el)
PE (1) PE20030942A1 (el)
PL (1) PL372238A1 (el)
PT (1) PT1476162E (el)
RS (1) RS60404A (el)
SI (1) SI1476162T1 (el)
SV (1) SV2004001485A (el)
TN (1) TNSN04159A1 (el)
TW (1) TW200307546A (el)
UA (1) UA77057C2 (el)
UY (1) UY27668A1 (el)
WO (1) WO2003070246A1 (el)
ZA (1) ZA200406276B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008770A (es) 2000-03-06 2004-09-10 Acadia Pharm Inc Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
MXPA04006280A (es) 2001-12-28 2004-09-27 Acadia Pharm Inc Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CA2490397A1 (en) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
WO2004064738A2 (en) 2003-01-16 2004-08-05 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
TW200505879A (en) 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
CA2528100A1 (en) 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
ATE451367T1 (de) 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
AU2005289635A1 (en) 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
WO2006080025A1 (en) * 2005-01-27 2006-08-03 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
US20090053329A1 (en) 2007-03-19 2009-02-26 Acadia Pharmaceuticals, Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
RU2147302C1 (ru) 1995-11-07 2000-04-10 Пфайзер Инк. 2-цианфенилтиопроизводные и способ получения 3-(1-пиперазинил)-1,2- бензизотиазола
IL126590A (en) 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
CN1635892A (zh) 2005-07-06
GT200300040A (es) 2007-01-12
CA2475302A1 (en) 2003-08-28
SI1476162T1 (sl) 2007-08-31
GEP20074030B (en) 2007-02-12
OA12774A (en) 2006-07-04
EP1476162A1 (en) 2004-11-17
UY27668A1 (es) 2003-10-31
EP1476162B1 (en) 2007-04-18
KR100773622B1 (ko) 2007-11-05
UA77057C2 (en) 2006-10-16
AP2004003103A0 (en) 2004-09-30
HRP20040711A2 (en) 2004-12-31
JP2005525347A (ja) 2005-08-25
DK1476162T3 (da) 2007-07-02
ZA200406276B (en) 2005-09-20
IL163277A (en) 2010-05-31
MA27177A1 (fr) 2005-01-03
NO20100584L (no) 2004-09-17
BR0307833A (pt) 2004-12-07
DE60313289D1 (de) 2007-05-31
SV2004001485A (es) 2004-05-07
IS7344A (is) 2004-07-05
JP4554938B2 (ja) 2010-09-29
ATE359787T1 (de) 2007-05-15
CA2475302C (en) 2009-05-12
AU2009202008A1 (en) 2009-06-11
WO2003070246A1 (en) 2003-08-28
PE20030942A1 (es) 2003-11-08
TNSN04159A1 (fr) 2007-03-12
KR20040086417A (ko) 2004-10-08
DE60313289T2 (de) 2007-12-27
AU2003206035A1 (en) 2003-09-09
ECSP045239A (es) 2004-09-28
MY139523A (en) 2009-10-30
NZ534443A (en) 2007-07-27
RS60404A (en) 2006-10-27
EA007866B1 (ru) 2007-02-27
TW200307546A (en) 2003-12-16
PL372238A1 (en) 2005-07-11
PA8567001A1 (es) 2003-12-10
MXPA04006993A (es) 2004-11-10
PT1476162E (pt) 2007-06-25
CO5611138A2 (es) 2006-02-28
CN101735212A (zh) 2010-06-16
AR038563A1 (es) 2005-01-19
ES2283745T3 (es) 2007-11-01
NO20043902L (no) 2004-09-17
EA200400815A1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
CY1114554T1 (el) Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CY1113054T1 (el) Παραγωγα διαμινης
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
CY1109462T1 (el) Συνθεση και διαδικασια εκχυλιση του διαλυτη μεταλλων χρησιμοποιωντας τους παραγοντες εκχυλισης αλδοξιμη ή κετοξιμη
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
ATE253063T1 (de) 5-ht1f-agonisten
CY1106682T1 (el) Ενωση λακταμης
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
ATE355104T1 (de) Haarbehandlungsmittel
SE9802937D0 (sv) Novel compounds
DE50310579D1 (de) Furancarboxamide
ID25478A (id) Agonis 5-ht1f
MXPA05012742A (es) Composiciones de tratamiento para el cabello.
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
CY1110796T1 (el) Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης
TW200503672A (en) 2-aminobenzoyl derivatives
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
TW200500350A (en) Photochromic oxazine compounds and methods for their manufacture
ITMO20020341A0 (it) Macchina operatrice perfezionata per la legatura di piante o simili.